Have you heard this? Nasal spray could help in treating obstructive sleep apnea in children. According to a recent article at Medical News Today, the ingredient fluticasone furoate in nasal spray may reduce the production of certain inflammatory cell proteins. Previous studies suggest that inflammation plays a role in OSAS, including the release of higher quantities of specific cytokines in the presence of inflammatory cytokines.
OSA syndrome occurs in 2% to 3% of children and can negatively impact their lives. Dr. Rania Esteitie and colleagues from The University of Chicago Medical Center and Pritzker School of Medicine studied a group of children ages 2 to 12 who were undergoing adenotonsillectomy for OSAS. Eleven children received fluticasone furoate nasal spray once daily for two weeks, while a control group of 13 children received no intranasal treatment. What researchers were looking for was the number of T-regulatory cells in both groups. After the surgery, researchers found the adenoids from children who were treated with nasal spray showed reduced levels of cytokine receptors secreted by T-regulatory cells and induce cell growth differentiation in certain cells—an important predictor of cardiovascular risk and mortality.
No comments:
Post a Comment